Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes

NCT00241423 · Completed

Last updated 2026-05-28

This clinical trial tested the effect of the medication exenatide on blood sugar levels over 24 hours in adults with type 2 diabetes, comparing it to a placebo.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 30 people

Who can join Ages 18–75 · all sexes

Timeline Started 2005-10 · est. completion 2007-06

Where 2 sites · United States

What this study is testing ClinicalTrials.gov NCT00241423 ↗

Description as written by the study sponsor.

The purpose of this study is to test the hypothesis that in patients with type 2 diabetes, the addition of exenatide will result in lower time-averaged serum glucose during a 24-hour period, compared with placebo.

Treatments tested

exenatide also known as Byetta, AC2993, synthetic enxendin-4 Drug

subcutaneous injection, 5mcg twice a day for one week; then 10 mcg twice a day for one week
Placebo Drug

subcutaneous injection, equivalent volume to 5 mcg exenatide twice a day for one week; then equivalent volume to 10 mcg exenatide twice a day for one week

Main thing measured	Time-averaged serum glucose during a 24-hour period
Sponsor	AstraZeneca
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00241423 ↗